AVCT
NEUTRALAvacta Completes Placing and TVR
The healthcare company has completed a placing and transaction to increase its share capital.
Avacta Group
72.00GBX
2.86%
Market Cap
293.95M
Volume
5.82M
230% of avg
P/E Ratio
-7.61
EPS (TTM)
-9.46
Beta
-0.47
Day Range
68.00p - 74.00p
52 Week Range
26.00p72.00p75.00p
72.00p
Upcoming Events
AVCT
NEUTRALAvacta presents promising preclinical data for dual payload cancer therapy
The biotechnology company has presented preclinical data on its innovative dual payload cancer therapy, which aims to overcome resistance and maximize tumor control.
AVCT
NEUTRALAvacta Group Announces Investor Presentation on Pre|CISION® Platform
The biopharmaceutical company will present data on its pre|CISION® oncology delivery platform at an investor event.
AVCT
NEUTRALAvacta Raises £16 Million Through Equity Fundraise
The biotechnology company has raised £16 million through a discounted equity placing to fund the advancement of its oncology pipeline.
AVCT
NEUTRALAvacta Presents Positive Phase 1a Data for Faridoxorubicin
The biopharmaceutical company has presented positive Phase 1a data for its lead program, faridoxorubicin, demonstrating favorable safety and tolerability as well as promising efficacy in certain cancer types.
AVCT
NEUTRALAvacta Presents Groundbreaking Dual Payload PDC Data at EORTC-NCI-AACR
The biopharmaceutical company announces it will present data on its first dual-payload PDC at an upcoming cancer therapeutics conference, showcasing its innovative oncology delivery platform.
AVCT
NEUTRALAvacta Reports Progress in Clinical Trials Amid Financial Challenges
The clinical-stage biotech firm reports progress in its cancer therapy trials, but faces financial headwinds with flat revenue and decreasing net assets.
AVCT
NEUTRALAvacta Group Provides Interim Results Update and ESMO Congress Details
The biotechnology company provides details on its upcoming interim results announcement and a change in the presentation at the ESMO Congress.
AVCT
NEUTRALAvacta's pre|CISION® Platform Shortlisted for AIM Technology of the Year Award
The biotechnology company has been shortlisted for a prestigious industry award, recognizing the potential of its innovative pre|CISION® platform.
AVCT
NEUTRALAvacta Completes Sale of Coris Bioconcept
The life sciences company has announced the completion of the sale of its subsidiary Coris Bioconcept SRL.